Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Reduce Prescription Drug Prices Background Between 2013 and 2015, spending on prescription drugs increased by 20 percent in the United States. Price increases impact millions of Americans as nearly 50 percent use at least one prescription drug in a given month. Drugs that treat complex, chronic conditions like Parkinson’s disease, epilepsy, migraine, and multiple sclerosis are particularly expensive. High prices directly impact patients and their treating providers as they work together to treat neurologic illness. Problem One in six people live with a brain or nervous system condition, and the annual cost of treating neurologic disorders in the United States is more than $500 billion. There have been massive increases in the prices of several neurology medications. For example, two multiple sclerosis drugs accounted for $1.9 billion in Medicare Part D catastrophic coverage in 2015 with average monthly prices of $5,600 each. This reflects an 84 percent increase in price from 2010 to 2015. Recently approved therapies for Duchenne muscular dystrophy and spinal muscular atrophy are expected to cost $500,000 and $750,000 in the first year of treatment, respectively. There are limited options to seek less expensive therapy but significant need for treatments for patients living with neurologic disease. Consequences Expensive drugs are a burden on the entire health care system as costs prices may be shifted and absorbed in ways that negatively impact patient and prescriber access to important medications. Action must be taken to ensure that prescription medications are accessible and affordable for all patients. Solution ¡¡ Support price negotiation for covered Medicare Part D drugs. Price negotiation would allow the government to leverage its purchasing power in an effort to obtain drugs at a lower price, bringing savings to the health care system and consumers. ¡¡ Promote transparency in prescription drug pricing. Disclosure of pricing information, including how drugs are priced, the prices paid by insurers, and the prices paid by consumers, would provide important information that could lower costs for patients and the entire health care system. ¡¡ Limit direct-to-consumer advertising. Advertisements create demand for unnecessary or inappropriate medications and marketing costs play a role in escalating drug prices. ¡¡ Support drug reimportation for medications of the same high quality. Many specialty drugs are priced significantly higher in the United States than in other countries. For example, the average monthly price of multiple sclerosis drug Copaxone is 287 percent greater in the United States than Switzerland. Reimportation offers an opportunity to offer lower cost medications. 201 Chicago Avenue • Minneapolis, Minnesota 55415 • tel: 800.879.1960 • fax: 612.454.2746 • www.aan.com